This isn’t a ‘biotech bubble,’ it’s ‘Philadelphia’s moment’ to become a center for gene therapy, says Penn-based CEO

“This is not a bubble, it’s Philadelphia’s moment,” Steven Nichtberger, CEO of Cabaletta Bio offers his perspective on the region’s exponential growth as the epicenter of cell and gene therapy.

Article from the Philadelphia Inquirer